ArticleNature communications2026
Autoinhibition of untimely DNA binding by structural disorder in the full-length peroxisome proliferator-activated receptors (PPARs).
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Structural disorder in nuclear receptors is essential for gene transcription, but mechanisms are lacking. Using experiment and computation, including residue-resolution NMR, we demonstrate how structural disorder in full-length peroxisome proliferator-activated receptors (PPARs) contributes to function. We show that the disordered AB domain of PPARγ and PPARα interact dominantly and dynamically with the DNA binding domain (DBD) via two regions that, when tested in cells, constitute active transactivation domains. For PPARγ, we provide an integrative structural model of the full-length protein, and show that upon DNA binding to the DBD, but not by ligand binding to the LBD, the AB domains are released to an open, accessible state. We demonstrate that the interactions between the AB domain and the DBD lead to autoinhibition affecting DNA binding affinity negatively with little effect on DNA binding specificity. We show that autoinhibition is also present in the heterodimer with RXRα, but is less pronounced due to higher DNA binding affinity. Thus, our work suggests a role for the disordered AB domain in preventing untimely DNA binding to the PPAR monomers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.